Engineered stem cells attacked glioblastoma grown in a lab
Original title: Engineered Mesenchymal Stem Cells Expressing CD::UPRT and TRAIL Exhibit Potent Anti-Tumor Effects in Glioblastoma Patient-Derived Organoids.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done on tumor samples grown in a lab dish.
The short version
Stem cells given tumor-killing genes killed off lab-grown tumor samples from four patients.
What was studied. Researchers built stem cells that carry two tumor-killing genes and home in on tumors. They tested these cells on lab-grown tumor samples made from four people with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary.
What they found. The treated tumor samples had more cell death and fewer living cells than untreated samples. The treated samples also spread out much less in a test of tumor growth. Markers of spreading and of tumor stem-like cells went down, while a normal brain cell marker stayed the same.
What this means, and what it doesn't
What it could mean: Stem cells may turn out to be a way to carry tumor-killing genes into a glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary. This is an early step that supports more testing of the idea.
What it doesn't mean: This was not a test in people. The work was done on tumor samples grown in a dish, which is the earliest stage of research. No one knows yet if it is safe or helpful in a real person. It is not something a doctor can offer, and it is not a cure.
Source: PubMed, September 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.